Ralfinamide. Newron Pharmaceuticals.
Cattabeni
Flaminio
F
University of Milano, Department of Pharmacological Sciences, Via Balzaretti 9, 20133 Milano, Italy. flaminio.cattabeni@unimi.it
D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D005464:Fluorobenzenes / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D006801:Humans; D010146:Pain / Q000188:drug therapy* / Q000209:etiology; D010523:Peripheral Nervous System Diseases / Q000150:complications*; D026941:Sodium Channel Blockers / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D013329:Structure-Activity Relationship
D005464:Fluorobenzenes; D026941:Sodium Channel Blockers; C499681:Ralfinamide